Chronic cholestatic liver injury attributable to vedolizumab

Jonathan G. Stine, Jennifer Wang, Brian W. Behm

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Drug-induced liver injury is a rare but clinically important diagnosis. Vedolizumab is an a4b7 integrin inhibitor recently approved for use in patients with moderate-to-severe inflammatory bowel disease. Cases of hepatoxicity due to vedolizu-mab in the pre-marketing stage were rare, and all cases resolved upon drug withdrawal. We present here the first reported case of hepatotoxicity attributable to vedolizumab, which despite drug cessation persisted with chronic choles-tatic liver injury.

Original languageEnglish (US)
Pages (from-to)277-280
Number of pages4
JournalJournal of Clinical and Translational Hepatology
Volume4
Issue number3
DOIs
StatePublished - 2016

All Science Journal Classification (ASJC) codes

  • Hepatology

Fingerprint

Dive into the research topics of 'Chronic cholestatic liver injury attributable to vedolizumab'. Together they form a unique fingerprint.

Cite this